Our findings demonstrate a positive correlation between FZD2 expression and TMB in cancers such as colorectal adenocarcinoma (COAD), supporting the hypothesis that FZD2 targeting could improve ICI efficacy, especially in tumors with high TMB. The gene discussed is FZD2; the disease is colorectal adenocarcinoma.